生物素化
表位
分子生物学
生物
嵌合抗原受体
单克隆抗体
体内
离体
细胞生物学
抗原
T细胞
抗体
免疫学
免疫系统
生物技术
作者
Xiuli Wang,Wen-Chung Chang,ChingLam W. Wong,David Colcher,Mark A. Sherman,Julie R. Ostberg,Stephen J. Forman,Stanley R. Riddell,Michael C. Jensen
出处
期刊:Blood
[American Society of Hematology]
日期:2011-06-09
卷期号:118 (5): 1255-1263
被引量:567
标识
DOI:10.1182/blood-2011-02-337360
摘要
Abstract An unmet need in cell engineering is the availability of a single transgene encoded, functionally inert, human polypeptide that can serve multiple purposes, including ex vivo cell selection, in vivo cell tracking, and as a target for in vivo cell ablation. Here we describe a truncated human EGFR polypeptide (huEGFRt) that is devoid of extracellular N-terminal ligand binding domains and intracellular receptor tyrosine kinase activity but retains the native amino acid sequence, type I transmembrane cell surface localization, and a conformationally intact binding epitope for pharmaceutical-grade anti-EGFR monoclonal antibody, cetuximab (Erbitux). After lentiviral transduction of human T cells with vectors that coordinately express tumor-specific chimeric antigen receptors and huEGFRt, we show that huEGFRt serves as a highly efficient selection epitope for chimeric antigen receptor+ T cells using biotinylated cetuximab in conjunction with current good manufacturing practices (cGMP)-grade anti-biotin immunomagnetic microbeads. Moreover, huEGFRt provides a cell surface marker for in vivo tracking of adoptively transferred T cells using both flow cytometry and immunohistochemistry, and a target for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo elimination. The versatility of huEGFRt and the availability of pharmaceutical-grade reagents for its clinical application denote huEGFRt as a significant new tool for cellular engineering.
科研通智能强力驱动
Strongly Powered by AbleSci AI